U.S. stock futures rose in the first full trading week of the year on Monday after closing mixed on Friday. Futures of major benchmark indices were higher.Over the weekend, the U.S. struck Venezuela and toppled Nicolás Maduro‘s regime. On Saturday, President Donald Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry, after the removal of President Maduro.The objective, as stated by Trump, is to restore Venezuela's dilapidated oil infrastructure and kick-start ...

Group 1 - Hong Kong's biotech fundraising momentum is projected to continue into 2026, driven by licensing deals and strong post-IPO trading, indicating renewed investor confidence in China's drug developers [1][2] - The domestic innovation sector is entering a harvest phase, with Chinese innovative drugs increasingly expanding into overseas markets, making biopharmaceutical stocks attractive [2] - Analysts highlight that while capital is returning to the biotech sector, it also emphasizes the underlying risks associated with the industry [3] Group 2 - Biotech is characterized as a high-risk, cash-intensive sector, with expectations of falling US interest rates and declining borrowing costs likely to attract more investors [4] - Several companies are in the IPO pipeline, including CSPC Innovation Pharmaceutical, which has commercialized two antibody drugs and two mRNA vaccines, and has a pipeline of 15 drug candidates [4] - Under Chapter 18A, companies like Jingze Biopharmaceutical and InventisBio have filed for Hong Kong IPOs, targeting various therapeutic areas, while Frontera Therapeutics aims to list as a clinical-stage gene therapy company [5] - Guangzhou Novaken Pharm is also an 18A applicant, developing drugs across multiple therapeutic areas, and the success of recent healthcare IPOs is encouraging more companies to seek fundraising in Hong Kong [6]

Shares of GH Research PLC (NASDAQ:GHRS) rose sharply in pre-market trading after the company announced it will provide an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression.GH Research shares jumped 18.1% to $15.64 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersMKDWELL Tech Inc (NASDAQ:MKDW) surged 61.2% to $0.27 in pre-market trading. MKDWELL Tech agreed to repurchase 34,580,000 ordinary shares at a price of $0.203/ ...

Core Insights - The stock market has shown strong performance in 2025, with major indices reaching record highs, indicating Wall Street's potential for wealth creation [1][2] Group 1: Visa - Visa has a strong track record, with shares climbing in 13 of the last 15 years, and only two declines of 0.3% and 3.3% in 2021 and 2022 respectively [4] - The company's performance is closely tied to economic growth, benefiting from increased consumer and business spending [5] - Visa's focus on payment facilitation rather than lending allows it to avoid capital set-asides for loan losses, enabling quicker recovery during economic downturns [6] Group 2: The Trade Desk - The Trade Desk is positioned for recovery in 2026, with midterm elections expected to boost ad spending [7] - The company's Unified ID 2.0 technology is gaining traction, which could enhance its pricing power and sustain double-digit sales growth [8] - Shares are currently valued at 18 times forward earnings, presenting a bargain compared to previous expectations of 20% to 40% annual sales growth [9] Group 3: Meta Platforms - Meta Platforms remains fundamentally attractive despite high market valuations, with its apps attracting an average of 3.54 billion daily users [11][12] - The introduction of generative AI solutions is expected to enhance ad pricing power and improve click-through rates [13] Group 4: UnitedHealth Group - UnitedHealth Group faced challenges in 2025 but has historically risen in 22 of the last 26 years [16] - The company is exiting unprofitable markets and plans to increase healthcare premiums, which should enhance its pricing power [17] - The Optum subsidiary is expected to rebound, potentially making UnitedHealth a top performer in 2026 [18] Group 5: Sirius XM Holdings - Sirius XM operates as a legal monopoly in satellite radio, generating over 75% of its revenue from subscriptions, which provides predictable cash flow [20][21] - The company has a forward P/E ratio of less than 7, representing a 46% discount to its five-year average [22][23] Group 6: BioMarin Pharmaceutical - BioMarin focuses on ultrarare-disease therapies, with its drug Voxzogo expected to exceed $1 billion in sales this year [25][26] - The company is streamlining operations and is projected to achieve mid-to-high single-digit sales growth in 2026 [27] Group 7: NextEra Energy - NextEra Energy has generated positive returns for investors in 21 of the last 24 years, benefiting from stable electricity demand [29] - The company leads in renewable energy capacity, which has reduced generation costs and supported high-single-digit EPS growth [30][31] Group 8: Okta - Okta provides essential cybersecurity services, with demand expected to grow as cyber threats persist [33][34] - The company's subscription backlog increased to nearly $4.3 billion, reflecting strong growth potential [35] Group 9: York Water - York Water is positioned for significant revenue growth if its proposed rate increase is approved, potentially increasing annual revenue by 32% [37][38] - The company has a long history of dividend payments, enhancing its appeal as a stable investment [39] Group 10: O'Reilly Automotive - O'Reilly Automotive has advanced in 21 of the last 23 years, benefiting from the increasing age of vehicles on the road [41] - The company's share-repurchase program has positively impacted its EPS, making it attractive to value investors [43]

Core Viewpoint - The article presents a list of 26 top dividend stocks for 2026, highlighting both established companies and new entrants in the dividend space [1]. Dividend Kings - AbbVie (NYSE: ABBV): A pharmaceutical company with a market cap of $405 billion and a forward dividend yield of 3%. It has successfully navigated a patent cliff with its drug Humira [3][4]. - The Coca-Cola Company (NYSE: KO): A multinational beverage maker with a market cap of $301 billion and a forward dividend yield of 2.9% [3]. - Walmart (NASDAQ: WMT): A large retailer with a market cap of $888 billion and a forward dividend yield of 0.8% [3]. High-Yield Dividend Stocks - Ares Capital (NASDAQ: ARCC): A leading publicly traded business development company (BDC) with a market cap of $14 billion and a forward dividend yield of 9.5% [6]. - Realty Income (NYSE: O): A large real estate investment trust (REIT) with a market cap of $52 billion and a forward dividend yield of 5.7%. It is noted for paying dividends monthly and has increased its dividend for 30 consecutive years [6][7]. Growth-Oriented Dividend Stocks - The article mentions the "Magnificent Seven" stocks, which are primarily recognized for their growth potential rather than dividends. However, some members of this group do offer dividends [8].

Core Viewpoint - Denmark's Novo Nordisk will launch its Wegovy weight loss pills at a price of $149 per month for self-paying patients in the United States starting January 5 [1] Group 1 - Novo Nordisk will offer two dosages of Wegovy: 1.5 milligrams and 4 milligrams [1]

ST人福公告，全资子公司湖北生物医药产业技术研究院有限公司收到国家药品监督管理局核准签发的 HW221043片的《药物临床试验批准通知书》。HW221043片拟用于晚期实体瘤的治疗，是由公司自主 研发的新分子实体化合物，目前国内外暂无同类药物获批上市。截至目前，HW221043片累计研发投入 约为2400万元人民币。 ...

Core Insights - TME Pharma N.V. provides updates on its research and development activities, focusing on its cancer and eye disease therapies [2] Group 1: NOX-E36 Developments - TME Pharma has initiated a subsequent study for NOX-E36 while terminating its collaboration with the Singapore Eye Research Institute for glaucoma filtration surgery, which is unrelated to the quality of NOX-E36 [3] - The company plans to launch studies in January 2026 to validate NOX-E36 detection in relevant animal models, facilitating local administration to patients [3][4] - TME Pharma believes that starting this new program will ease the search for new partners to advance NOX-E36 through collaboration, sale, or joint venture [4] Group 2: Market Potential - Fibrosis significantly contributes to treatment failure in glaucoma filtration surgery and is a critical factor in several eye diseases affecting approximately 30 million people in the US, highlighting the market potential for anti-fibrotic therapies like NOX-E36 [5] Group 3: NOX-A12 Developments - TME Pharma is actively discussing potential partnerships for the NOX-A12 program and has kept the glioblastoma clinical trial open for resumption upon finding a suitable partner [6] Group 4: Financial Strategy - As of June 30, 2025, TME Pharma has approximately €2.0 million in cash, reflecting a responsible treasury policy and strict cost control, with no investments made in cryptocurrencies despite a new treasury policy allowing such investments [7] - The company signed a non-binding Letter of Intent with a German Resource Development Company (GRDC) and is conducting due diligence, with shareholder approval contingent on positive outcomes [8] Group 5: Strategic Restructuring - Under the leadership of the new CEO, TME Pharma is undergoing strategic restructuring to unlock the value of its lead assets, NOX-A12 and NOX-E36, while exploring acquisitions and partnerships in stable, profitable businesses to support its drug development [11][18]

Core Viewpoint - The company announced that the regulator has accepted a priority review to potentially expand the age range for its Tzield type-1 diabetes drug to include children as young as one year old [1] Group 1 - The priority review indicates a significant step towards making the Tzield drug available for younger patients [1]

Core Viewpoint - The FDA has accepted a supplemental biologic license application for Tzield to expand its age indication to children as young as one year old, aiming to delay the onset of stage 3 type 1 diabetes in patients diagnosed with stage 2 T1D [1][2]. Group 1: FDA Review and Study Data - The FDA's priority review highlights the urgent need for innovative therapies like Tzield, which may prevent the progression of T1D by delaying the loss of insulin production [2][3]. - The application is supported by positive interim one-year data from the ongoing PETITE-T1D phase 4 study, which evaluates Tzield's safety and pharmacokinetics in young children [1][4]. - The target action date for the FDA's decision on the application is April 29, 2026 [1]. Group 2: Study Details - The PETITE-T1D study is a phase 4, single-arm, non-randomized, open-label trial designed to assess Tzield's safety and pharmacokinetics in children under eight years diagnosed with stage 2 T1D [4]. - The study has enrolled 23 participants, with a treatment regimen consisting of an intravenous infusion of Tzield once daily for 14 consecutive days, and individual follow-up may last up to 26 months [5]. Group 3: Tzield Overview - Tzield (teplizumab-mzwv) is a CD3-directed monoclonal antibody and the first disease-modifying therapy for autoimmune T1D, initially approved in the US in November 2022 for patients aged eight and older [6]. - Tzield is also approved in several countries, including China, the UK, Canada, and others, for delaying the onset of stage 3 T1D in the same population [6]. - If approved for younger patients, Tzield would be the first therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D [8].